Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2013-08-16

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01924637

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: oral placebo
Drug: semaglutide

First Posted Date: 2013-08-15

Last Posted Date: 2021-01-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 632

Registration Number: NCT01923181

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: metformin
Drug: sulphonylurea

First Posted Date: 2013-08-07

Last Posted Date: 2017-08-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 343

Registration Number: NCT01917656

Locations: 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: insulin degludec/liraglutide

First Posted Date: 2013-08-05

Last Posted Date: 2013-11-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT01916174

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: sitagliptin
Drug: placebo

First Posted Date: 2013-07-25

Last Posted Date: 2018-10-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 407

Registration Number: NCT01907854

Locations: 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Diabetes
Healthy

Interventions: Other: No treatment given

First Posted Date: 2013-07-17

Last Posted Date: 2016-10-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 61

Registration Number: NCT01900834

Locations: 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin detemir
Drug: other injectable antidiabetic treatment regimens

First Posted Date: 2013-07-04

Last Posted Date: 2019-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2446

Registration Number: NCT01892319

Locations: 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 50
Drug: biphasic human insulin 50

First Posted Date: 2013-07-03

Last Posted Date: 2015-07-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 161

Registration Number: NCT01892020

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2013-07-02

Last Posted Date: 2015-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 952

Registration Number: NCT01890993

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: exenatide

First Posted Date: 2013-06-24

Last Posted Date: 2019-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 813

Registration Number: NCT01885208

Locations: 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy